REQUEST A DEMO
Total
USD $0.00
Search more companies

Novo Nordisk Pharma D.O.O. Beograd (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Novo Nordisk Pharma D.O.O. Beograd Profile Updated: October 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Novo Nordisk Pharma D.O.O. Beograd is an enterprise located in Serbia, with the main office in Belgrade. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. It was first established on August 29, 2005. It currently has a total number of 63 (2023) employees. In its most recent financial highlights, the company reported a net sales revenue increase of 8.7% in 2023. Its’ total assets recorded a growth of 54.95%. In 2023, Novo Nordisk Pharma D.O.O. Beograd’s net profit margin decreased by 0.81%.

Headquarters
Milutina Milankovica 9 B
Belgrade; Belgrade; Postal Code: www.novonordisk.rs

Contact Details: Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.

Website: http://CUBE_PROFILES_YU

Basic Information
Total Employees:
Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.
Outstanding Shares:
Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.
Registered Capital:
Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.
Incorporation Date:
August 29, 2005
Key Executives
Purchase this report to view the information.
Chairman of the Supervisory Board
Purchase this report to view the information.
Member of the Supervisory Board
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Novo Nordisk Pharma D.O.O. Beograd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
8.7%
Total operating revenue
8.7%
Operating profit (EBIT)
-24.99%
EBITDA
-24.86%
Net Profit (Loss) for the Period
-16.01%
Total assets
54.95%
Total equity
33.52%
Operating Profit Margin (ROS)
-1.64%
Net Profit Margin
-0.81%
Return on Equity (ROE)
-14.8%
Quick Ratio
-0.28%
Cash Ratio
-0.02%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?